Health Condition 1: null- Persons with epilepsy undergoing antiepileptic drug tapering after more than 2 years of seizure free period
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed persons with epilepsy (PWE) 2. Either male or female, age more than 18 years 3. On monotherapy of AEDs (valproic acid, carbamazepine, phenytoin and levetiracetam) 4. Two years seizure freedom or longer 5. PWE going to start AED tapering 6. Patient ready to give informed consent
Exclusion criteria
Exclusion criteria: 1. Juvenile myoclonic epilepsy 2. Pregnant or seeking pregnancy 3. Associated neurological diseases other than epilepsy 4. Patient on drugs known to alter seizure threshold (e.g. INH, theophylline, metronidazole etc.) 5. Patient with significant hepatic and renal impairment that may require dose alteration 6. Patient on anti tubercular drugs or any other drugs known to cause interaction with AEDs (e.g. isoniazid, fluoxetine, fluvoxamine, clarithromycin, erythromycin, fluconazole etc.) 7. Patient on food or dietary supplements like grape fruit juice and ginkgo biloba which are known to cause interaction with AEDs 8. Any associated psychiatric disorder 9. Any chronic inflammatory disorder (e.g. Autoimmune disorder like RA, IBD, bronchial asthma) 10. Patient refuses to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of seizure recurrence in PWE on monotherapy undergoing AED tapering with minimum 1 year follow up periodTimepoint: 1 year follow up period | — |
Secondary
| Measure | Time frame |
|---|---|
| ï?? Correlation between the lowering of serum AED concentration with seizure recurrence in PWE on monotherapy undergoing AED taperingTimepoint: 1 year follow up period;ï?? Correlation of the following factors with seizure recurrence with treatment, seizure, inflammatory biomarkers- TNF alpha, IL-1 betaTimepoint: 1 year follow up period | — |
Countries
India
Contacts
All India Institute of Medical Sciences, New Delhi